BioCorRx/ US09073C2052 /
2024-04-19 9:51:25 PM | Chg. 0.0000 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.4700USD | 0.00% | 2,656 Turnover: 3,681.0800 |
-Bid Size: - | -Ask Size: - | 1.4800 | 1.0500 |
GlobeNewswire
04-03
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and S...
GlobeNewswire
02-28
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for R...
GlobeNewswire
02-08
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
GlobeNewswire
01-09
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
GlobeNewswire
2023-08-15
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Na...
Newsfile Corp
2022-07-06
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podca...
Newsfile Corp
2022-04-19
BioCorRX Inc. Discusses FDA Approval Process for Implantable Naltrexone Pellet, BICX104, with The St...
GlobeNewswire
2022-02-14
BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical ...
GlobeNewswire
2021-12-09
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board
GlobeNewswire
2021-10-07
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant